RCAMU
HRMY icon

Rothschild & Co Asset Management US’s Harmony Biosciences HRMY Stock Holding History

Rothschild & Co Asset Management US’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$9.1M Sell
165,088
-27,167
-14% -$1.49M 0.14% 115
2022
Q3 		$8.52M Sell
192,255
-19,414
-9% -$947K 0.15% 117
2022
Q2 		$10.3M Sell
211,669
-5,068
-2% -$228K 0.16% 115
2022
Q1 		$10.5M Sell
216,737
-65,297
-23% -$2.66M 0.13% 132
2021
Q4 		$12M Sell
282,034
-17,985
-6% -$717K 0.14% 160
2021
Q3 		$11.5M Buy
+300,019
New +$9.66M 0.14% 167

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Rothschild & Co Asset Management US's HRMY Position: Q4 2022 in Review

Rothschild & Co Asset Management US reduced its Harmony Biosciences (HRMY) stake by 14% in Q4 2022, selling an estimated $1.49M and leaving 165,088 shares worth $9.1M. The position accounts for 0.14% of the portfolio, ranked #115.

Rothschild & Co Asset Management US first reported a position in HRMY in Q3 2021 and has held it in 6 quarters since. The position peaked at $12M in Q4 2021. 242 funds tracked by Wall St. Rank hold HRMY as of Q4 2022.

  • Rothschild & Co Asset Management US held 165,088 shares of Harmony Biosciences worth $9.1M as of Q4 2022.
  • Rothschild & Co Asset Management US sold 27,167 Harmony Biosciences shares in Q4 2022, an estimated $1.49M.
  • Harmony Biosciences made up 0.14% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #115 holding.
  • Rothschild & Co Asset Management US first reported a position in Harmony Biosciences in Q3 2021 and has held it in 6 quarters since.
  • Rothschild & Co Asset Management US's Harmony Biosciences position peaked at $12M in Q4 2021.
  • 242 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.